Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap)

Ding Y, Yeh SH, Mink CM, Zangwill KM, Allred NJ, Hay JW

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details
Ding Y, Yeh SH, Mink CM, Zangwill KM, Allred NJ, Hay JW. Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) Vaccine 2013; 31(22): 2558-2564

PubMedID
23583811

DOI
10.1016/j.vaccine.2013.03.053

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Cost-Benefit Analysis; Decision Trees; Diphtheria-Tetanus-acellular Pertussis Vaccines /administration & dosage /adverse effects /economics; Female; Humans; Infant; Mothers; Postpartum Period; United States; Vaccination /economics; Whooping Cough /economics /prevention & control /therapy

AccessionNumber
22013016521

Date bibliographic record published
07/05/2013